Custom Product Briefs

Public View

Whether you're running low on time or have an upcoming value analysis meeting, ECRI Institute's on-demand Product Brief Service makes it easy for hospitals and health plans to submit questions about new brand-name healthcare technologies.

Get the Answers You Need

Take the stress out of your search for answers on brand-name drugs and devices. In a customized three- to six-page ultra-rapid review, we provide a product overview, probe manufacturer claims, list relevant clinical studies and regulatory information, and offer our independent, bottom-line recommendations to answer your questions, allowing you to separate the hype from the evidence. All completed Product Briefs are added to our database.

This service is available as part of our Health Technology Assessment Information Service.

 Make quicker, evidence-based decisions

​In addition to an executive summary, you get a product overview and information on:

  • The Evidence Bar™. ECRI Institute’s proprietary approach to weighing the benefits and harms of a specific, name-brand drug or device shows one of five possible indicators about the evidence: unfavorable, raises concerns, inconclusive, favors, or greatly favors the technology.
  • Purported benefits. See manufacturer claims on a brand-name drug or device.
  • Regulatory status. Has the Food and Drug Administration addressed the need for this type of intervention?
  • Clinical literature. What does the clinical literature say?
  • Safety. Have there been any reported safety issues related to this product?
  • ECRI Institute bottom-line opinions. Our experts offer unbiased, evidence-based guidance on how to proceed with a specific technology.

Depending on the technology and the available evidence, we also offer information on current diagnostics, current treatments, and point of testing.

 Sample Product Briefs



ReEBOV Antigen Rapid Test (Corgenix Medical Corp.) for Diagnosing Ebola Virus Disease Antigen Rapid Test (Corgenix Medical Corp.) for Diagnosing Ebola Virus Disease3/13/2015 12:00:00 AM ​The ReEBOV™ Antigen Rapid Test is a point-of-care assay intended to quickly diagnose Ebola virus disease in patients with signs and symptoms who may have been exposed to the virus. FDA granted Emergency Use Authorization for the test in February 2015 to detect the Zaire strain.